Business Daily from THE HINDU group of publications
Friday, Sep 19, 2008
ePaper | Mobile/PDA Version | Audio

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Consulting
Get Latest Quote and Company Info
Ranbaxy hires Giuliani as advisor on USFDA move

Ex-NY Mayor to review compliance issue highlighted by regulator.


With the addition of Mr Giuliani, Ranbaxy reiterates its commitment to cooperate with the FDA to address the Import Advisory


Our Bureau

New Delhi, Sept 18 In a bid to minimise the impact due to the block imposed by US Food and Drug Administration, Ranbaxy Laboratories Ltd has retained the services of former New York City Mayor Mr Rudy Giuliani and Giuliani Partners to provide advice and review compliance issues highlighted by the US drug regulator.

The USFDA has blacklisted about 30 generic drugs being manufactured by the company at its Dewas and Paonta Sahib plants in India. The US drug regulator said that it had taken the decision after the two units owned by Ranbaxy failed to meet the standards specified under the current Good Manufacturing Practice (GMP) requirements of the US Government.

While the FDA has not imposed a ban on the drugs or sought a withdrawal of the medicines from US drugstores, it has issued an Import Alert, under which US officials may detain any products manufactured at these Ranbaxy facilities.

Announcing the appointment of Mr Giuliani, Ranbaxy said, “In announcing the addition of Mr Giuliani, Ranbaxy reiterated its commitment to work cooperatively with the FDA to address the Import Advisory and put into place measures which will allow its products identified on the Advisory to be released into the US marketplace.”

“As the FDA stated, all drugs manufactured by Ranbaxy have repeatedly tested safe and effective with no adverse incidents reported. Ranbaxy is committed to a swift resolution to address these issues and to continuing to supply the global market place with safe and effective pharmaceuticals,” the company added.

While the FDA acknowledged that it has no evidence that Ranbaxy has shipped defective products, it has informed the company that until Ranbaxy resolves the deficiencies at each of the two facilities it will not approve any New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs) that list the Paonta Sahib or Dewas plants as the manufacturer.

Ranbaxy’s Rs 5 shares closed 9 per cent down on the NSE on Thursday at Rs 341.45.

Related Stories:
US blocks 30 Ranbaxy drugs
Generic drug makers’ concern over Ranbaxy-USFDA stand-off
Ranbaxy: Uncertainty about USFDA investigation

More Stories on : Consulting | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page




Stories in this Section
Sundram Fasteners board appointment


Suven Life to raise $50 m
RINL staff wins awards
Arun Nanda gets top French honour
Ranbaxy hires Giuliani as advisor on USFDA move
UB Group looking to spin off subsidiaries
Lupin buys majority stake in S African pharma co
EoIs invited for titanium complex
Jai Balaji to begin work on Bengal plant by year-end
AO Smith setting up facility in Bangalore
Apollo Hospitals to build medical health records repository
Karnataka offers 1,000 acres for Nano plant
Dr Reddy’s launches subsidiary in US
Reliance submits EoI for gas supply to 6 TN cities
NTPC planning to scale up nuclear power capacity
BHPV board to be reconstituted soon
Lehman fall will not hit projects, says Bharat Infratech
BHEL targets Rs 45,000 cr turnover by 2011-12
Strides Arcolab plans domestic launch of branded drugs, nutraceuticals




Brandline



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line